Next week, Pure MHC will take part in the annual Immunotherapy & Vaccine Summit (IMVACS) in Boston, which showcases clinical advancement of immune therapies through technology and innovation. Pure MHC will present some of its newest research into targeting cancer cells and the potential therapies that could evolve from it.
Dr. William Hildebrand, Chief Scientist at Pure MHC, is presenting as part of the Target Discovery for T Cell Therapy event on August 26 & 27. The focus of these two days is on current and emerging targets for CAR (Chimeric Agent Receptors), TCR (T Cell Receptor Targets), and TIL (Tumor Infiltrating Lymphocytes).
Dr. Hildebrand’s presentation, scheduled for 12:15 PM on August 27 and titled, “Identification and Targeting of HLA/Peptide Targets Distinct to Cancerous Tissue,” will discuss Pure MHC’s work in identifying HLA (human leukocyte antigen)/peptide complexes for targeting specific types of cancer cells.
Pure MHC possesses technology for the generation of antibodies that mimic T cell receptors, a potent immune system cell. Called “TCRms,” these bind specifically to peptide-HLA complexes on the surfaces of tumors. TCRms can be used to develop antibody drug conjugates or bi-specific antibody products capable of recruiting immune cells to kill TCRm-decorated tumors.
“T Cell research is moving forward at astounding speed,” said Dr. Hildebrand. “IMVACS provides the venue and opportunity to show key professionals in our field the value of Pure MHC’s technologies, plus it gives us the chance to understand how our work fits into the bigger picture of T Cell therapies.”
Dr. Hildebrand has been a CLIA-Accredited Clinical HLA Laboratory Director and an American Board for Histocompatibility and Immunogenetics Diplomat since 1998. He has been awarded over $40M in grants from Oklahoma and federal government agencies as well as from private corporations.
To date, he has authored over 120 publications, reviews, and book chapters in peer-reviewed industry works as well as popular science journal; he was Associate Editor of the Journal of Immunology from 2006-2010. Dr. Hildebrand has served on editorial, advisory, and national review panel boards including that for the Center for HIV/AIDS Vaccine Immunology (CHAVI), the American Society for Hematology, the National Institute for Allergy and Infectious Diseases, and the National Marrow Donor Program.
He has appeared on numerous radio and television news programs and in public service announcements highlighting his research; likewise, he is a frequent invited keynote speaker and advisor to international conferences and private industry companies. Dr. Hildebrand holds 77 patents (issued or pending) in fields related to the discovery and use of the soluble HLA protein technology he has developed.
The conference will be held at the Boston Marriott Long Wharf Hotel, as part of the 10th annual Immunotherapy and Vaccine Summit. For more details on the event, visit the conference website at www.imvacs.com/t-cell. To learn more about Pure MHC, visit www.puremhc.com.